Ovid Therapeutics & Takeda Announce Agreement for Soticlestat
- Ovid Pharmaceuticals is eligible to receive up to $856M in payments, including a $196M upfront payment, regulatory and commercial milestone payments and tiered double-digit royalties on product sales
- Potential first-in-class therapy reduced seizure frequency in children with Dravet syndrome and Lennox-Gastaut syndrome in Phase 2 ELEKTRA study
- Original 2017 collaboration between Ovid and Takeda to conclude; Ovid will have no further development or milestone obligations
- Takeda plans to initiate Phase 3 studies in children and . . .
This content is for paid subscribers.Today’s Highlights March 3, 2021